NEW YORK (GenomeWeb News) – Teva Pharmaceuticals will be the exclusive distributor of MDxHealth's tests for prostate cancer and glioblastoma in Israel under a deal announced today.

The three-year agreement provides Teva the exclusive rights to distribute MDxHealth's ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma in Israel. MDxHealth will analyze samples in its CLIA-registered laboratory in Irvine, Calif., and Teva will reimburse MDxHealth for all testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.